Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Keyphrases

Publications

2023

Abram L Wagner, Felicia Zhang, Kerry A Ryan, Eric Xing, Paige Nong, Sharon L R Kardia, Jodyn Platt
US Residents' Preferences for Sharing of Electronic Health Record and Genetic Information: A Discrete Choice Experiment. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Clara Mukuria, Tessa Peasgood, Emily McDool, Richard Norman, Donna Rowen, John Brazier
Valuing the EQ Health and Wellbeing Short (EQ-HWB-S) using time trade-off and a discrete choice experiment: A feasibility study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Amanda W Erbe, Dana Kendzia, Ellen Busink, Suzanne Carroll, Eline Aas
Value of an Integrated Home Dialysis Model in the United Kingdom: A Cost-Effectiveness Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Qinglu Cheng, Evan B Cunningham, Sophy Shih, Janaki Amin, Julie Bruneau, Adelina A Artenie, Jeff Powis, Alain H Litwin, Curtis Cooper, Olav Dalgard, Margaret Hellard, Philip Bruggmann, Philippa Marks, Karine Lacombe, Catherine Stedman, Phillip Read, Behzad Hajarizadeh, Adrian J Dunlop, Brian Conway, Jordan J Feld, Gregory J Dore, Jason Grebely, null null
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Christopher J Cadham, Lisa A Prosser
Eliciting Trade-Offs Between Equity and Efficiency: A Methodological Scoping Review. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
G Emmanuel Guindon, Erica Stone, Riya Trivedi, Sophiya Garasia, Kimia Khoee, Alexia Olaizola
The associations of prescription drug insurance and cost-sharing with drug use, health services use, and health - a systematic review of Canadian studies. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Tommi Tervonen, Ashley Duenas, Hannah Collacott, Annette Lam, Katharine S Gries, Robin Carson, Nicola Trevor, Nicolas Krucien, Jianming He
Current Health State Affected Patient Preferences more than Disease Status: A Discrete Choice Experiment in Multiple Myeloma. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Fanni Rencz, Valentin Brodszky, Mathieu F Janssen
A direct comparison of the measurement properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health instruments and EQ-5D-5L and PROPr utilities in a general population sample. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Ari Gnanasakthy, Courtney Levy, Lindsey Norcross, Lynda Doward, Randall Winnette
A Review of Labeling based on PRO endpoints for new oncology drugs approved by the European Medicines Agency (2017-2021). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Lieven Annemans
Innovative Public Price Mechanisms for Market Access of Innovative Medicines: A Marriage Between Cost-Effectiveness, Medical Need, and Budget Impact. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Stacie Hudgens, Scottie Kern, Alexandra I Barsdorf, Sally Cassells, Alison Rowe, Bellinda L King-Kallimanis, Cheryl Coon, Geoff Low, Sonya Eremenco
Best Practice Recommendations for Electronic Patient-Reported Outcome (ePRO) Dataset Structure and Standardization to Support Drug Development. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Mo Yang, Helene Vioix, Emma S Hook, Anthony J Hatswell, Rachael L Batteson, Bruce R Gaumond, Aurora O'Brate, Sanjay Popat, Paul K Paik
Health Utility Analysis of Tepotinib in Patients with Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Josephine A Mauskopf, Khalid M Kamal
Drug Pricing Throughout the Product Lifecycle: A Work in Progress. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Linda A Murphy, Ron Akehurst, Oriol Solà-Morales, David Cunningham, Jorge Mestre-Ferrandiz, Matthew Franklin, Gérard de Pouvourville
The Real-World Evidence Workstream In EUreccA 2025: How the task was addressed. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Viktoriia Dobrova, Kseniia Ratushna, Oleksii Popov, Anna Bezruk, Ivan Loboda
Reimbursement Program "Affordable Medicines" In Ukraine: The Framework Assessment And Impact Evaluation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Viktoriia Dobrova, Kseniia Ratushna, Oleksii Popov, Anna Bezruk, Ivan Loboda
The "Affordable Medicines" Reimbursement Program in Ukraine:Framework Assessment and Impact Evaluation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Salah Ghabri
Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Step Forward. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Gérard de Pouvourville, David Cunningham, Frank-Ulrich Fricke, Peter Lindgren, Lorenzo Mantovani, Linda A Murphy, Oriol Solà-Morales, Jorge Mestre-Ferrandiz, Ron Akehurst
Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Jedidiah I Morton, Clara Marquina, Dianna J Magliano, Jonathan E Shaw, Zanfina Ademi
Targeting diabetes prevention to more disadvantaged groups improves cost-effectiveness: Implications of inequality in type 2 diabetes from theoretical interventions. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Abram L Wagner, Felicia Zhang, Kerry A Ryan, Eric Xing, Paige Nong, Sharon L R Kardia, Jodyn Platt
US residents' preferences for sharing of electronic health record and genetic information: a discrete choice experiment. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Juliane Schiller, Helene Eckhardt, Sarah Schmitter, Valerie A Alber, Tanja Rombey
Challenges and solutions for the benefit assessment of tumor-agnostic therapies in Germany. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Carolina Iglesias-Lopez, Antònia Agustí, Antoni Vallano, Mercè Obach
Financing and reimbursement of approved advanced therapies in several European countries. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Carolina Iglesias-López, Antònia Agustí, Antoni Vallano, Mercè Obach
Financing and Reimbursement of Approved Advanced Therapies in Several European Countries. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Ron Akehurst, Linda A Murphy, Oriol Solà-Morales, David Cunningham, Jorge Mestre-Ferrandiz, Gérard de Pouvourville
Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties and a Pragmatic Way Forward. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)
Mikel Berdud, Niklas Wallin-Bernhardsson, Bernarda Zamora, Peter Lindgren, Adrian Towse
The Allocation of the Economic Value of Second-generation Antipsychotics Over the Product Life-cycle: the Case of Risperidone in Sweden and the UK. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2023)

volume 26, number 2, 2023

John F P Bridges, Esther W de Bekker-Grob, Brett Hauber, Sebastian Heidenreich, Ellen Janssen, Alice Bast, Janel Hanmer, Andriy Danyliv, Eric Low, Jacoline C Bouvy, Deborah A Marshall
A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (2) (2023)

volume 26, number 3, 2023

Viktoriia Dobrova, Kseniia Ratushna, Oleksii Popov, Anna Bezruk, Ivan Loboda
The "Affordable Medicines" Reimbursement Program in Ukraine: Framework Assessment and Impact Evaluation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Josephine A Mauskopf, Khalid M Kamal
Drug Pricing Throughout the Product Lifecycle: A Work in Progress. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Viktoriia Dobrova, Kseniia Ratushna, Oleksii Popov, Anna Bezruk, Ivan Loboda
The "Affordable Medicines" Reimbursement Program in Ukraine: Framework Assessment and Impact Evaluation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Lieven J P Annemans
Innovative Public Price Mechanisms for Market Access of Innovative Medicines: A Marriage Between Cost-Effectiveness, Medical Need, and Budget Impact. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Josephine A Mauskopf, Khalid M Kamal
Drug Pricing Throughout the Product Lifecycle: A Work in Progress. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Mikel Berdud, Niklas Wallin-Bernhardsson, Bernarda Zamora, Peter Lindgren, Adrian Towse
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Mikel Berdud, Niklas Wallin-Bernhardsson, Bernarda Zamora, Peter Lindgren, Adrian Towse
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Newell E McElwee
Does the United States Need Better Policies Governing Generic Drug Use? Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Mikel Berdud, Niklas Wallin-Bernhardsson, Bernarda Zamora, Peter Lindgren, Adrian Towse
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Viktoriia Dobrova, Kseniia Ratushna, Oleksii Popov, Anna Bezruk, Ivan Loboda
The "Affordable Medicines" Reimbursement Program in Ukraine: Framework Assessment and Impact Evaluation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Deirdre Mladsi, Christine L Barnett, Gregory Mader, T Alexander Russell-Smith, Aig Unuigbe, Tim Bell
The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Lieven J P Annemans
Innovative Public Price Mechanisms for Market Access of Innovative Medicines: A Marriage Between Cost-Effectiveness, Medical Need, and Budget Impact. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Newell E McElwee
Does the United States Need Better Policies Governing Generic Drug Use? Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Josephine A Mauskopf, Khalid M Kamal
Drug Pricing Throughout the Product Lifecycle: A Work in Progress. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Mikel Berdud, Niklas Wallin-Bernhardsson, Bernarda Zamora, Peter Lindgren, Adrian Towse
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Deirdre Mladsi, Christine L Barnett, Gregory Mader, T Alexander Russell-Smith, Aig Unuigbe, Tim Bell
The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Newell E McElwee
Does the United States Need Better Policies Governing Generic Drug Use? Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Deirdre Mladsi, Christine L Barnett, Gregory Mader, T Alexander Russell-Smith, Aig Unuigbe, Tim Bell
The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)
Lieven J P Annemans
Innovative Public Price Mechanisms for Market Access of Innovative Medicines: A Marriage Between Cost-Effectiveness, Medical Need, and Budget Impact. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (3) (2023)

volume 26, number 4, 2023

Tommi Tervonen, Jorien Veldwijk, Katherine Payne, Xinyi Ng, Bennett Levitan, Leila G Lackey, Kevin Marsh, Praveen Thokala, Francesco Pignatti, Anne Donnelly, Martin Ho
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (4) (2023)

volume 26, number 5, 2023

Paul O'Donohoe, David S Reasner, Sarrit M Kovacs, Bill Byrom, Sonya Eremenco, Alexandra I Barsdorf, Valdo Arnera, Stephen Joel Coons
Updated Recommendations on Evidence Needed to Support Measurement Comparability Among Modes of Data Collection for Patient-Reported Outcome Measures: A Good Practices Report of an ISPOR Task Force. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (5) (2023)
Paul O'Donohoe, David S Reasner, Sarrit M Kovacs, Bill Byrom, Sonya Eremenco, Alexandra I Barsdorf, Valdo Arnera, Stephen Joel Coons
Updated Recommendations on Evidence Needed to Support Measurement Comparability Among Modes of Data Collection for Patient-Reported Outcome Measures: A Good Practices Report of an ISPOR Task Force. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (5) (2023)

volume 26, number 7, 2023

Chris J Edgar, Elizabeth Nicki Bush, Heather R Adams, Rachel Ballinger, Bill Byrom, Michelle Campbell, Sonya Eremenco, Fiona McDougall, Elektra Papadopoulos, Ashley F Slagle, Stephen Joel Coons
Recommendations on the Selection, Development, and Modification of Performance Outcome Assessments: A Good Practices Report of an ISPOR Task Force. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (7) (2023)

volume 26, number 8, 2023

Evelien Moorkens, Teresa Barcina Lacosta, Dalia Dawoud, András Inotai, Manthan Janodia, Chia Jie Tan, Ka Keat Lim, Nishtha Khatri, Catarina Lopes Pereira, Steven Simoens
A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 26 (8) (2023)